Clinical Trial Update: The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)

View source ↗

Summary

A clinical trial evaluating whole-body MRI in metastatic castration-resistant prostate cancer patients treated with Lu-PSMA has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (Lutetium-177-PSMA-617) (Lutetium-177-PSMA-617)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC) | Status: TERMINATED